title: Can RNAi-mediated hsp90α knockdown in combination with 17-AAG be a therapy for glioma?
abstract: Heat shock protein 90 promotes tumor progression and survival and has emerged as a vital therapeutic target. Previously we reported that the combinatorial treatment of 17AAG/sihsp90α significantly downregulated Hsp90α mRNA and protein levels in Glioblastoma Multiforme (GBM). Here we investigated the ability of cell penetrating peptide (Tat48-60 CPP)-mediated siRNA-induced hsp90α knockdown as a single agent and in combination with 17-allylamino-17-demethoxygeldanamycin (17-AAG) to induce tumor growth inhibition in GBM and whether it possessed therapeutic implications. GBM and non-tumorigenic cells exposed to siRNA and/or 17-AAG were subsequently assessed by qRT-PCR, immunofluorescence, FACS analysis, quantitative Akt, LDH leakage and cell viability assays. PAGE was performed for serum stability assessment. A combination of siRNA/17-AAG treatment significantly induced Hsp90α gene and protein knockdown by 95% and 98%, respectively, concomitant to 84% Akt kinase activity attenuation, induced cell cycle arrest and tumor-specific cytotoxicity by 88%. Efficient complex formation between CPP and siRNA exhibited improved serum stability of the siRNA with minimal intrinsic toxicity in vitro. The preliminary in vivo results showed that combination therapy induced hsp90α knockdown and attenuated Akt kinase activity in intracranial glioblastoma mouse models. The results imply that RNAi-mediated hsp90α knockdown increases 17-AAG treatment efficacy in GBM. In addition, the cytotoxic response observed was the consequence of downregulation of hsp90α gene expression, reduced Akt kinase activity and S-G2/M cell cycle arrest. These results are novel and highlight the ability of Tat to efficiently deliver siRNA in GBM and suggest that the dual inhibition of Hsp90 has therapeutic potentials.
authors.affiliation: Brain Tumour North West (BTNW), Faculty of Science and Technology, University of Central Lancashire (UCLan), Preston PR1 2HE, UK.
authors.forename: Adi
authors.initials: A
authors.lastname: Mehta
authors.forename: Amal
authors.initials: A
authors.lastname: Shervington
authors.forename: John
authors.initials: J
authors.lastname: Howl
authors.forename: Sarah
authors.initials: S
authors.lastname: Jones
authors.forename: Leroy
authors.initials: L
authors.lastname: Shervington
keywords: Akt; Cell penetrating peptides; Cell-cycle arrest; GBM; Glioblastoma; Hsp90 inhibitor; Hsp90α; Tat; sihsp90α/CPP complex
references.citation: Cancer Invest. 2010 Jul;28(6):608-14
references.pmid: 20210521
references.citation: Am J Transl Res. 2010 Jan 01;2(1):19-42
references.pmid: 20182580
references.citation: BMC Cancer. 2010 Sep 09;10:481
references.pmid: 20828379
references.citation: J Control Release. 2010 May 10;143(3):335-43
references.pmid: 20079391
references.citation: Oncogene. 2007 Nov 8;26(51):7185-93
references.pmid: 17525741
references.citation: Clin Cancer Res. 2007 Mar 15;13(6):1625-9
references.pmid: 17363512
references.citation: Bioconjug Chem. 2007 Sep-Oct;18(5):1450-9
references.pmid: 17711319
references.citation: Biochem Pharmacol. 2012 Apr 15;83(8):1033-40
references.pmid: 22209713
references.citation: Adv Drug Deliv Rev. 2012 Oct;64(13):1508-21
references.pmid: 22975009
references.citation: Cancer Invest. 2008 Nov;26(9):900-4
references.pmid: 18798074
references.citation: Curr Opin Pharmacol. 2006 Oct;6(5):509-14
references.pmid: 16860608
references.citation: Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):530-6
references.pmid: 18155315
references.citation: Chem Biol. 2010 Jul 30;17(7):735-44
references.pmid: 20659686
references.citation: FASEB J. 2007 Sep;21(11):2664-71
references.pmid: 17463227
references.citation: J Cell Sci. 2005 Aug 1;118(Pt 15):3339-51
references.pmid: 16079278
references.citation: Hum Gene Ther. 2010 Apr;21(4):417-26
references.pmid: 19899955
references.citation: J Pharm Sci. 2007 Nov;96(11):2922-30
references.pmid: 17518360
references.citation: Intervirology. 2009;52(3):135-40
references.pmid: 19478527
references.citation: J Neurol Neurosurg Psychiatry. 2004 Jun;75 Suppl 2:ii2-11
references.pmid: 15146033
references.citation: Mol Cell Biochem. 2006 Feb;283(1-2):1-9
references.pmid: 16444580
references.citation: Cancers (Basel). 2011 Dec 08;3(4):4228-44
references.pmid: 24213135